10 Unusual Stocks Attracting Huge Interest In The Market Right Now

vladimirputin wink tbi

Here’s where we see the heat this morning:

Today we have huge results from Gazprom, bullish words from Delta, China’s trying to block BHP’s Potash buy, plus some wild pharma catalysts, and more…

HUGE DEAL: Orexigen (OREX) gets $1bn marketing deal with Takeda for their obesity drug, stock going nuts already

MACAU BABY: Markets seem to be pretty happy about Melco Crown's (MPEL) latest Macau revenue

High volume, over 41,000 shares as of 8:09 AM. Read about the Macau data here.

ADR WATCH: Natural gas giant Gazprom's profit triples (ADRs are OGZPY)

Read about it here. See the stock performance in Russia here.

M&A: On second thought, being bought out isn't as easy as it looks for Burger King (BKC)... shares losing some speculative steam

EARNINGS: Canada's leading Toronto Dominion Bank (TD) misses estimates by a sliver, but profit up 29%

SAME STORE SALES: Costco (COST) blows away analyst estimates

Same store sales rise 7% in August vs. 4.2% expected. Read about it here.

BULLISH OUTLOOK: Delta (DAL) says August traffic very strong

M&A: China reportedly trying to block BHP's potential takeover of fertiliser giant Potash (POT)

PHARMA CATALYST: Drug maker Cardiome (CRME) nails $30 million milestone payment

MICRO CAP BAGS A DEAL: Amtech (ASYS) gets $37 million of solar orders, not bad when your market cap is just $128 million

ODD: Spine device maker Alphatec (ATEC) running up pre-market and has a wild chart

Might be worth a look. Forbes called it THE biggest biotech loser here.

PHARMA CATALYST: Cerus (CERS) reports positive outcome from blood treatment study with the Red Cross

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at research.businessinsider.com.au.